[EN] PPAR AGONISTS AND METHODS OF USE THEREOF<br/>[FR] AGONISTES DE PPAR ET LEURS MÉTHODES D'UTILISATION
申请人:SALK INST FOR BIOLOGICAL STUDI
公开号:WO2016057322A1
公开(公告)日:2016-04-14
Provided herein are deuterated compounds and compositions useful in increasing PPAR5 activity. The compounds and compositions provided herein are useful for the treatment of PPAR5 related diseases (e.g., muscular diseases, vascular disease, demyelinating disease, and metabolic diseases).
Provided herein are compounds and compositions useful in increasing PPARδ activity. The compounds and compositions provided herein are useful for the treatment of PPARδ related diseases (e.g., muscular diseases, vascular disease, demyelinating disease, and metabolic diseases).
Provided herein are deuterated compounds and compositions useful in increasing PPARδ activity. The compounds have a formula
where L5 comprises at least one deuterium. Exemplary species include
The compounds and compositions provided herein are useful for the treatment of PPARδ related diseases (e.g., muscular diseases, vascular disease, demyelinating disease, and metabolic diseases).
Provided herein are compounds and compositions useful in increasing PPARδ activity. The compounds and compositions provided herein are useful for the treatment of PPARδ related diseases (e.g., muscular diseases, vascular disease, demyelinating disease, and metabolic diseases).